



Therapeutic Apheresis Services Patient Experience Survey

Summary of results from November 2018 Survey



Elaine Howe – Service Development Manager Olivia Pirret – Data Analyst Administrator

Executive Summary

Therapeutic Apheresis Services (TAS) is part of NHS Blood & Transplant's (NHSBT) Diagnostic and Therapeutic Services (DTS) directorate and delivers services to adults and children from a range of clinical specialties in Trusts based across eight geographical regions.

In line with its strategic plan, TAS performs an annual patient experience survey to measure the level of patient satisfaction with its services. This report presents the outcomes of a Patient Experience Survey (PES) given to patients in all units over a four-week period in November/December 2018, the results of which will be compared against the outcomes of the previous surveys.

This survey evaluated the views of adult and paediatric patients/donors (or their carer/relative) who received treatment from TAS in Bristol, Leeds, Liverpool, Manchester, Oxford, Birmingham, Sheffield and London.

Obtaining information on patient experience and acting on the outcomes to improve future experience is a requirement of the standards set out by the Care Quality Commission. The survey focuses on care and hospitality aspects of the service, staff demeanour and information provision. The same survey was used at all locations.

In 2013 in line with its strategic plan, TAS established a base-line of patient satisfaction with annual surveys thereafter. The survey, conducted in 2013, set a baseline top box score of 95%. Top box scores are the percentage of answers scoring 9/10 or 10/10 to a key question on overall satisfaction. In this survey the top box question is Q7 'Your overall satisfaction of our service'.

Answers to a total of 8 questions were scored on a scale of 1 (poor) to 10 (excellent) with extremely positive results from all locations

Results

- The top box score for overall experience (Q7) in 2018 is 97%.
 - Feedback from the survey was assessed using top box scores (the percentage of answers scoring 9 or 10 out of 10) and average scoring methods as in previous surveys, with an average score of 9.9 (from a range of 7-10).
- There was an overall survey response rate of 83%.
 228 patient experience surveys were issued to adult and paediatric patients/donors (or their carer/relative) and a total of 189/228 patient experience surveys were returned.
- 75% of patients treated within the specified survey timeframe had the opportunity to comment on their TAS experience.
- The quantitative data was accompanied by qualitative comments and overall feedback is very positive, indicating a high level of satisfaction from TAS patients.
 - Top box scores* for all questions were above the target of 95%, and the only area previously below the target of 95% (welcome & introduction) increased to 96% from 94% in 2017.

*The top box result is similar to that of the Friends and Family Test used in the wider NHS

Table 1 shows a comparison of the overall top box score by question for the last two surveys

2017 result	2018 result	% change
94%	96%	+2%
98%	97%	-1%
98%	98%	
98%	96%	-2%
98%	96%	-2%
100%	98%	-2%
97%	97%	
100%	97%	-3%
	94% 98% 98% 98% 98% 100% 97%	94% 96% 98% 97% 98% 98% 98% 96% 98% 96% 100% 98% 97% 97%

Background/Overview

Between 19th November and 14th December 2018, a total of 228 patient experience surveys were given to adult and paediatric patients/donors (or their carer/relative) who received treatment from TAS in Bristol, Leeds, Liverpool, Manchester, Oxford, Birmingham, Sheffield and London.

The medical and nursing teams deliver a wide range of therapeutic apheresis treatments to patients from across England.

The treatments are provided using specialist machines which exchange, remove, or collect certain components within the blood through a process called Therapeutic Apheresis, which can then allow secondary treatment processes to take place. Patients/donors completing the survey were undergoing a variety of treatments including:

- Therapeutic Plasma Exchange
- Automated Red Cell Exchange
- Peripheral Blood Stem Cell Collection
- Platelet Depletion
- White Cell Depletion
- Low Density Lipid Removal
- Extracorporeal Photopheresis

Obtaining information on patient experience and acting on the outcomes to improve future experience is a requirement of the standards set out by the Care Quality Commission. The survey focuses on care and hospitality aspects of the service, staff demeanour and information provision. The same survey was used at all locations.

Method

A paper-based survey was handed out to patients/donors and/or their family members or carers when attending the TAS unit or when attended to by TAS staff as an in-patient. Option was given to either complete the survey at the time of the appointment/treatment, or at a later date (a freepost return envelope was provided). Anonymity was maintained for all respondents.

The survey was carried out over a period of 4 weeks during November/December 2018 and consisted of quantitative data collection in the form of eight specific questions relating to all aspects of Therapeutic Apheresis Services' treatment. Each question was scored on a scale of 1 (totally dissatisfied) to 10 (totally satisfied) and additional qualitative comments fields were provided for all questions (for a copy of the survey see appendix 1).

The results of the surveys were inputted by each unit and data analysis then commenced on 16th January 2019. Data from the questionnaires was analysed using Microsoft Excel.

Key Highlights of the Results

- The 2018 survey was given out to 228 of 304 patient treated within TAS, which gave 75% of patients treated within the specified survey timeframe the opportunity to comment on their TAS experience.
- 189 of 228 surveys given to patients were returned giving an overall response rate of 83%.
- 87% of responses were received from the patient/donor themselves, with the remaining 13% received from a relative/carer.
- 7% of the responses received related to patients participating in clinical research and/or trial activity.
- The percentage of the total number of patients treated returning the survey varied across the country, with 33% of patients returning the survey in Manchester compared to 81% of patients returning the survey in Sheffield.
- There is variability in the response rates received from patients by procedure type with 83% of
 patients having a Peripheral Blood Stem Cell collection responding in comparison to 53% of these
 patients undergoing an automated red cell exchange.

Table 2 shows response rate information by unit

Unit	Surveys issued	Surveys returned	Surveys not returned	Response rate	Patients treated	Patients given survey	Patients retuning survey
Birmingham	9	9	0	100%	15	60%	60%
Bristol	49	35	14	71%	65	75%	54%
Leeds	31	29	2	94%	39	79%	74%
Liverpool	24	22	2	92%	35	69%	63%
London	25	20	5	80%	31	81%	65%
Manchester	25	13	12	52%	40	63%	33%
Oxford	38	35	3	92%	47	81%	74%
Sheffield	27	26	1	96%	32	84%	81%
Total	228	189	39	83%	304	75%	62%

Table 3 shows the top box, average and range of scores by question

		Thi	s Survey (20	18)	Previ	ous Survey (2017)
#	Question	Top Box Score	Average Score	Range	Top Box Score	Average Score	Range
1	Welcome & Introduction	96%	9.8	5 - 10	94%	9.8	1 - 10
2	Care & Support	97%	9.9	7 - 10	98%	9.8	1 - 10
3	Patient Involvement	98%	9.9	7 - 10	98%	9.9	8 - 10
4	Information Received	96%	9.9	6 - 10	97%	9.8	5 - 10
5	Cleanliness	96%	9.9	7 - 10	98%	9.9	5 - 10
6	Professionalism of Staff	98%	9.9	8 - 10	100%	9.9	9 - 10
7	Overall Experience	97%	9.9	7 - 10	97%	9.9	7 - 10
8	Likeliness to Recommend	97%	9.9	8 - 10	100%	10.0	9 - 10

Chart 1 shows the top box and average score by question




Table 4 shows the top box score by question and unit

Table Tallette		000,000,	quiocitori ai						
Unit	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Total
Birmingham	88%	100%	100%	88%	67%	100%	100%	89%	91%
Bristol	94%	97%	97%	94%	97%	100%	100%	100%	97%
Leeds	97%	97%	97%	93%	97%	100%	97%	100%	97%
Liverpool	100%	100%	100%	100%	100%	100%	100%	100%	100%
London	85%	90%	90%	90%	85%	90%	90%	85%	88%
Manchester	100%	100%	100%	100%	100%	100%	92%	100%	99%
Oxford	97%	100%	100%	97%	100%	100%	97%	100%	99%
Sheffield	100%	96%	100%	100%	100%	96%	96%	96%	98%

Chart 2 shows the top box score by question for the last five surveys




Table 5 shows the scores received by unit

Score			5		6		7		8		9		10
Birmingham	2							6	8.82%	9	13.24%	53	77.94%
Bristol	≥	1	0.36%					6	2.18%	7	2.55%	261	94.91%
Leeds	pelow			1	0.43%	1	0.43%	5	2.16%	5	2.16%	220	94.83%
Liverpool										5	2.84%	171	97.16%
London	res					5	3.13%	14	8.75%	13	8.13%	128	80.00%
Manchester	scol							1	0.97%	9	8.74%	93	90.29%
Oxford	S O							3	1.07%	25	8.93%	252	90.00%
Sheffield	Ž					1	0.48%	3	1.44%	4	1.92%	200	96.15%
Total		1	0.08%	1	0.08%	7	0.53%	38	2.87%	72	5.43%	107	91.03%

Chart 3 shows the top box score for question 7 (overall experience) for the current and previous surveys




Chart 4 shows the percentage of perfect scores (10 out of 10) by question




Table 6 shows the responses received by procedure type

Unit	Auto PBSC	Related PBSC	Unrelated PBSC	Total PBSC	PEX	ECP	LDL	RCX	Other*
Birmingham	0	0	0	0	0	0	0	9	0
Bristol	6	0	0	7	3	17	3	2	2
Leeds	10	2	0	13	6	0	0	10	0
Liverpool	6	0	0	6	3	12	0	1	0
London	4	1	1	6	4	4	0	4	4
Manchester	1	0	0	1	0	12	0	0	0
Oxford	10	1	0	12	12	8	0	1	2
Sheffield	3	0	16	20	3	0	0	0	3
Total	40	4	17	65	29	53	3	27	11
Patients treated	d		•	78	55	95	6	58	11
Return Rate				83%	53%	56%	50%	47%	100%

^{*}Other includes: Lymphocyte collections, White Cell Depletions, and Platelet Depletions



Key development areas identified for action:

To improve response rates there is a need to better understand and capture:

- Why only 75% of patients treated in the survey period were given the opportunity to respond to the experience survey
- The variability (52% to 100%) of response rates across the eight TAS units who were participating in the trial
- The response rates of patients depending on treatment type (54% to 100%)

In addition

- There is currently no official patient forum that TAS patients can access to help feedback experience and drive the direction of service provision.
- The survey and all previous Patient Experience Surveys have been conducted in a paper format which is an outdated and labour-intensive process.

Next Steps:

- The results of the survey will be shared with each TAS unit, who will work in collaboration with their clinical colleagues to review their area results and produce an individualised action plan to address any areas for improvement.
- Lead Nurses to discuss team action plans addressing any individual patient comments with their Senior Nurse Manager.
- TAS Operational Management team to review national results for the Patient Experience Survey to better understand the variability in return rate.
- Service Development Manager to raise an agenda item and provide relevant background information for discussion at TAS Senior Management Team meeting regarding future format of gathering patient experience data.
- The final Patient Experience report to be distributed and made available to all internal and external stakeholders
- A review of how patient experience within TAS is captured is required, with consideration placed on the type of information and the ideal frequency of gathering information, to ensure that feedback and actions to address concerns are timely.
- To come in line with the wider NHS digital vision, TAS must look to conduct future patient experience data gathering exercises utilising a paperless approach.
- TAS to look at developing a patient forum to enable patients to have a voice on the strategic direction of services.


NHS Blood & Transplant

NHS Blood & Transplant (NHSBT) saves and improves lives by providing a safe, reliable and efficient supply of blood and associated services to the NHS in England. We are the organ donor organisation for the UK and are responsible for matching and allocating donated organs.

We rely on thousands of members of the public who voluntarily donate their blood, organs, tissues and stem cells. Their generosity means each year we're able to supply around 1.9 million units of blood to hospitals in England and around 4,200 organ and 5,800 tissue donations, which save or improve thousands of lives.

For more information about the Patient Experience Survey or Therapeutic Apheresis Services

Email TherapeuticApheresisServices@nhsbt.nhs.uk Call 0117 921 7407









NHS Blood and Transplant

Please help us to improve our service by taking a few moments to complete this short feedback form. Your feedback is very important in helping us to identify how we can improve any aspects of our service and the care our patients and their families receive during their visit.
If you would like assistance to complete this form, please ask a family member, friend, or any member of our team.
Please be assured that your feedback is completely anonymous.
Please indicate whether you are the:
☐ Patient/Donor
☐ Patient's Relative/Carer
Please indicate the reason you attended the unit:
Stem cell collection
☐ Plasma exchange
☐ Photopheresis
Lipid (cholesterol) removal
☐ Red cell exchange
Other (please detail)
Was your procedure performed as part of a clinical/research trial?
Yes
□ No

	1ª Visit
	Between 6 and 10
	More than 10 — ongoing treatment
are	you are having a stem cell collection, you donating your stem cells to meone? Yes - a relative
a	Yes - an unrelated party
	No
	N/A
	ease give specific details or examples in comment boxes.
sco	ease also indicate your satisfaction with ore between 1 $\stackrel{"}{ $
	How satisfied were you with the Icome you received?
	1 2 3 4 5 6 7 8 9 10
Но	ow can we improve?

*	1	2	3	4	5	6	7	8	9	10	6
Hov	v со	uld v	we (do b	ette	r?					
			en serie	220022	0255	000000	00f500		10122-111	224	
				ed w nyo							۵,
114		-		2	0 0	- 6	_		1	-	1
6	1	2	3	4	5	6	7	8	9	10	6
101	v co	uld v	we I	nave	e inv	OIV	ed y	rou	mor	e/	
101	v co	uld v	we	nave	e inv	OIV	ed y	rou	HOI	e?	
101	v co	uld	we	nave	e inv	OIV	ed y	rou	HOI	e?	
101	v co	uld	we	nave	e inv	OIV	ed y	rou	mor	er	
101	v co	uld	we	nave	e inv	OIV	ed y	ou	mor	e/	
101	v co	uld	we	nave	e inv	OIV	ed y	rou	mor	e?	
101	v co	uld	we	nave	e inv	OIV	ed y	rou	mor	er_	
101	v co	uld	we	nave	e inv	OIV	ed y	rou	mor	er_	
100	v co	uld	we	nave	e inv	OIV	ed y	rou	mor	e/	
4. I	How	v sat	tisfi	ed v	were	e yo	ou w				
4. I	How	v sat	tisfi		were	e yo	ou w				
4. I	How	sat	tisfi n yo	ed v	were	e yo	ou w	vith	the		
4. I	low	v sat	tisfi	ed v	were	e yo	ou w] 📢
4. I nfo	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10]
4. H	How orma	sat ation	tisfi n yo	ed v	were ecei	e yo	ou w	vith 8	the	10] (
4. I nfo	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10]
4. I nfo	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10] (
4. H	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10] (
4. H	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10]«
4. H	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10] «
4. H	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10] «
4. H	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10] «
4. Hinfo	How orma	sat ation	tisfi n yo	ed vou re	were ecei	e yo	ou w	vith 8	the	10]«